SavedAdd your journal

Journals / Marmara Medical Journal / 2008 / Cilt: 21 - Sayı: 1

-

ALS PATOFİZYOLOJİSİ: NEYİ, NE KADAR BİLİYORUZ?

Kayıhan ULUÇ
Barış İŞAK
TÜLİN TANRIDAĞ
Önder US
Pages
102–111
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Amyotrofik lateral skleroz (ALS) esas olarak serebral korteks, beyin sapı ve spinal korddaki motor nöronları etkileyen progresif seyirli nörodejeneratif bir hastalıktır. Çoğu vakanın sporadik olduğu ALS’de familyal geçiş %5-10’dur ve bunların yaklaşık olarak %10-20’sinde neden süperoksid dismutaz-1 enziminde meydana gelen mutasyondur. Familyal ve sporadik vakaların klinik ve patolojik bulguları birbirlerine büyük benzerlikler göstermektedir. Bu özgün derleme yazısında ALS’nin patofizyolojisinde etkili olduğu öne sürülen mekanizmalar varsayımsal tümleyici bir model ile tartışılacaktır.

🔖

Cite This Article

ULUÇ, K., İŞAK, B., TANRIDAĞ, T., US, Ö. (2008). -. Marmara Medical Journal, Cilt: 21 - Sayı: 1, 102–111. https://ajindex.com/articles/284047

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994;124 Suppl:96-107
  2. Goetz CG. Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 2000;23:336-343
  3. Nelson LM. Epidemiology of ALS. Clin Neurosci 1995;3:327-331
  4. Beghi E, Logroscino G, Chio A, et al. The epidemiology of ALS and the role of populationbased registries. Biochim Biophys Acta 2006;1762(11-12):1150-1157
  5. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000;57:1171-1176
  6. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362(6415):59-62
  7. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 2005;5:77-87
  8. Vandenberghe N. [Where is the role of the genetic investigations in ALS?]. Rev Neurol (Paris) 2006;162 Spec No 2:4S96-94S101
  9. Beckman JS, Estevez AG, Crow JP, Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 2001;24(11 Suppl):S15-20
  10. Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Genet 1998;19:171-174
  11. Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002;26:438-458
  12. Rothstein JD, Bristol LA, Hosler B, Brown RH, Jr., Kuncl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994;91:4155-4159
  13. Greenlund LJ, Deckwerth TL, Johnson EM, Jr. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995;14:303-315
  14. Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996;13:43-47
  15. Esteve